Cancel
Korro Bio
Korro Bio Employees
7 people indexed:
-
jxx0qu@t2ddd498.2jv Sign up to see email
-
92z036j@jxfhff8t.j27 Sign up to see email
-
y5yqu4t@qxa6p8qv.d54 Sign up to see email
-
vyjw7pw3a@x12p13f4.ddn Sign up to see email
-
qx0fzw82w@yj25ufnq.fz6 Sign up to see email
-
f3ewdgf68g3z76@4q52fwlf.p5p Sign up to see email
-
64qt92h1@py555eqq.3su Sign up to see email
Korro Bio Company Information
Korro Bio, headquartered in Cambridge, MA, is a biotechnology firm that develops RNA editing technologies to create innovative medical treatments. Founded with the mission to lead in RNA editing, the company utilizes its proprietary platform, Oligonucleotide Promoted Editing of RNA (OPERA), to advance its research and development efforts. Korro Bio has successfully raised $70 million through a private placement to support its RNA editing programs and an additional $116 million specifically for its OPERA RNA editing program. The company is particularly focused on diseases where RNA editing can offer unique therapeutic benefits, with a strong emphasis on targeting conditions affecting the liver and central nervous system. Korro Bio is planning to initiate a First-in-Human study for its KRRO-110 in patients with Alpha-1 Antitrypsin Deficiency in the second half of 2024.
Report inaccurate information
Report inaccurate information